INS and colorectal cancer: Over a 15-year period, in a study of 1,221,218 drug-naive patients with T2D, it was found that GLP1As reduced the risk of colorectal cancer compared to insulin, metformin, SGLT2 inhibitors, sulfonylureas, and thiazolidinediones.